Navigation Links
Discovery in Nature elucidates immune cells in skin and supports novel vaccine approach
Date:2/29/2012

BOSTON, MA February 29, 2012 TREM Rx, Inc., a biotechnology company with a proprietary technology platform for novel vaccines delivered to the skin, announced today the results of an in vivo preclinical study that shows, for the first time, that powerful cells of the immune system called TREMs (T Resident Effector Memory cells) prevalent in the skin can mediate a protective immune response that is far stronger than memory T cells that circulate in the bloodstream. The study was published in today's online edition of Nature and was led by TREM Rx scientific founder, Dr. Thomas S. Kupper, the Thomas B. Fitzpatrick Professor of Dermatology at Harvard Medical School, and chair of Dermatology at Brigham and Women's Hospital and the Dana Farber Cancer Institute.

This research and previous work by Dr. Kupper's group demonstrated that a stronger generalized T cell immune response, and in particular a more robust TREM response, can be produced by delivering a viral vaccine vector to the upper skin tissues, as compared to below the skin or into the muscle. This new research reveals why novel vaccines administered to upper layers of the skin in preclinical models have demonstrably better preventative and therapeutic efficacy over conventional vaccine injection into the muscles or bloodstream. TREM Rx has exclusive rights to this vaccine-relevant intellectual property as the basis for the company's proprietary technology platform for developing novel vaccines.

"Conventional vaccines are typically focused on optimizing the B cell arm of the immune system to create disease-fighting antibodies. In contrast, this study shows that a more effective path to immunity may be to engage this newly discovered part of the T cell arm of the immune system through a population of powerful immune cells that we now know reside in the skin, lung, gut, and other epithelial tissues," said Thomas S. Kupper, MD, senior author of the Nature paper.

"Putting this research in historical context, it helps explain the uniquely powerful efficacy of the first successful vaccine developed for smallpox by Jenner in 1796," said Kupper. "Syringes had not yet been invented, so Jenner administered the first vaccine by disrupting the upper layers of skin with a specialized needle, a process similar to how the vaccinia virus was delivered in our study. It is worth remembering that the smallpox vaccine remains the most effective vaccine in the history of medicine, resulting in the elimination of smallpox in human populations."

In the preclinical study in Nature, vaccinia virus delivered to the skin was found to rapidly recruit viral-specific T cells, called TREMs (T Resident Effector Memory cells), not just to the infected site, but also to all areas of the skin. These TREMs remained in skin, and provided rapid and effective protection against a second infection from the same virus. While skin was used as a model system in the study, the results are relevant to epithelial cells in the lungs, GI tract, and other epithelial tissues that are sites of viral entry to the body.

The findings of this study challenge immunological dogma by suggesting that the most important elements of T cell memory and immunity to infectious diseases may reside in skin and other epithelial tissues mediated by TREMs, rather than by circulating T or B cells in the blood. With regard to the impact on vaccine design and delivery, the study suggests that vaccines to generate TREM can be optimized by delivery through epithelial tissues, for a potentially more effective immune response than is achieved with conventional vaccine injection.

"This groundbreaking research provides a major opportunity to develop a new class of vaccines with improved preventative and therapeutic efficacy that can potentially have a major impact on human health," said Eric Stromquist, president of TREM Rx. "We are committed to translating this new understanding of protective immunity to the design of novel vaccines for a wide range of applications, including important infectious diseases and cancers."


'/>"/>

Contact: Barbara Yates
barbara@theyatesnetwork.com
781-258-6153
The Yates Network
Source:Eurekalert

Related biology technology :

1. Thomson Reuters Cortellis Drives Drug Discovery and Development With Powerful New Web Services
2. Discovery opens door to low-cost negative refraction, new products and industries
3. AnaptysBio Announces New Strategic Antibody Discovery
4. Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era
5. Discovery of a dark state could mean a brighter future for solar energy
6. Cellular Dynamics Announces Commercial Launch of iCell® Neurons for Neuroscience Drug Discovery
7. Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research
8. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
9. GlaxoSmithKline and the University of Edinburgh Agree to Collaborative Partnership for Drug Discovery
10. MIABE standard opens up new opportunities in drug discovery
11. Malaria discovery gives hope for new drugs and vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 18, 2017 , ... The American Medical Informatics ... its Data Sharing Policy. Specifically, the nation’s leading informatics experts, said data sharing ... existing policy. AMIA recommended that NIH earmark funding for researchers to produce and ...
(Date:1/19/2017)... YORK , Jan. 18, 2017 ... to reach USD 92.9 billion by 2025, according ... Inc. Pharmaceutical industry has been adaptive of the ... as early as 2002. Among the services outsourced, ... forerunners. For instance, Johnson & Johnson was the ...
(Date:1/18/2017)... ... January 18, 2017 , ... Opal Kelly, a ... or PCI Express, announced the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed ... business-card sized form factor suitable for prototyping, testing, and production-ready integration. The ZEM5310 ...
(Date:1/18/2017)... --  Parent Project Muscular Dystrophy (PPMD) , a nonprofit ... dystrophy (Duchenne) , today announced a $600,000 grant to ... (NJIT) and Talem Technologies (Talem) as part of the ... assist people living with Duchenne. PPMD is funding a ... computer, software, a force sensor and a motor – ...
Breaking Biology Technology:
(Date:1/11/2017)... DES MOINES, Iowa , Jan. 11, 2017 /PRNewswire/ ... another industry first with the release of its patent-pending ... to quickly and reliably perform calibrations, securely upload data ... more flexibility for the customer. "Fighting drunk ... not only for the public at large, but also ...
(Date:1/6/2017)...  Delta ID Inc., a leader in consumer-grade iris ... at CES® 2017. Delta ID has collaborated with Gentex ... use of iris scanning as a secure, reliable and ... a car, and as a way to elevate the ... Delta ID and Gentex will demonstrate (booth #7326 LVCC) ...
(Date:12/22/2016)...  As part of its longstanding mission to improve genetic ... recently released its latest children,s book, titled The ... the topics of inheritance and variation of traits that are ... elementary school classrooms in the US. The ... Ariana Killoran , whose previous book with 23andMe, ...
Breaking Biology News(10 mins):